Recipharm

Recipharm, originally founded in Sweden and now headquartered in Switzerland, is a leading global Contract Development and Manufacturing Organization (CDMO) universally recognized for its extensive manufacturing network and deep, specialized expertise across a wide variety of pharmaceutical dosage forms. Recipharm stands out in the highly competitive global CDMO market through its operational scale and tremendous versatility, efficiently operating a strategic footprint of advanced manufacturing and R&D facilities across Europe, India, Israel, and North America.

The company provides highly comprehensive services encompassing early-stage complex formulation development, highly regulated clinical trial material manufacturing, and large-scale commercial drug product production. Recipharm’s technical capabilities are vast, expertly covering oral solid doses, complex semi-solids, and highly sensitive steriles. They are globally renowned for their advanced, highly secure sterile fill-and-finish capabilities, including complex lyophilization and advanced auto-injector and pen assembly.

In recent years, recognizing the future of medicine, Recipharm has aggressively and successfully expanded into the advanced therapeutics space, establishing its specialized Advanced Bio (ReciBioPharm) division to strictly focus on the development and manufacturing of complex modalities like biologics, viral vectors, mRNA, and lipid nanoparticles (LNPs).

Coupled with a strategic streamlining of its core network to focus on high-value drug delivery and biologics, Recipharm’s robust quality systems, global reach, and enduring Swedish heritage make it a top-tier, highly reliable partner for both massive pharmaceutical entities and innovative biotech firms.